These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 7981310)

  • 21. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization.
    Tobery TW; Siliciano RF
    J Exp Med; 1997 Mar; 185(5):909-20. PubMed ID: 9120397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
    Fuller DH; Haynes JR
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1433-41. PubMed ID: 7888198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses.
    Kent SJ; Stallard V; Corey L; Hu SL; Morton WR; Gritz L; Panicali DL; Greenberg PD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):551-60. PubMed ID: 7917517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
    Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
    DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1.
    McElrath MJ; Rabin M; Hoffman M; Klucking S; Garcia JV; Greenberg PD
    J Virol; 1994 Aug; 68(8):5074-83. PubMed ID: 8035507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys.
    Barouch DH; Craiu A; Kuroda MJ; Schmitz JE; Zheng XX; Santra S; Frost JD; Krivulka GR; Lifton MA; Crabbs CL; Heidecker G; Perry HC; Davies ME; Xie H; Nickerson CE; Steenbeke TD; Lord CI; Montefiori DC; Strom TB; Shiver JW; Lewis MG; Letvin NL
    Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4192-7. PubMed ID: 10759543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques.
    Venet A; Bourgault I; Aubertin AM; Kiény MP; Levy JP
    J Immunol; 1992 May; 148(9):2899-908. PubMed ID: 1349322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
    Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev.
    Blazevic V; Ranki A; Krohn KJ
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1335-42. PubMed ID: 8573390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient antigen presentation to cytotoxic T lymphocytes by cells transduced with a retroviral vector expressing the HIV-1 Nef protein.
    Robertson MN; Buseyne F; Schwartz O; Rivière Y
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1217-23. PubMed ID: 7511396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
    J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses.
    Liu LJ; Watabe S; Yang J; Hamajima K; Ishii N; Hagiwara E; Onari K; Xin KQ; Okuda K
    Vaccine; 2001 Oct; 20(1-2):42-8. PubMed ID: 11567744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single-chain variable fragments.
    Ho WZ; Lai JP; Bouhamdan M; Duan L; Pomerantz RJ; Starr SE
    AIDS Res Hum Retroviruses; 1998 Nov; 14(17):1573-80. PubMed ID: 9840290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-HIV env immunities elicited by nucleic acid vaccines.
    Shiver JW; Davies ME; Yasutomi Y; Perry HC; Freed DC; Letvin NL; Liu MA
    Vaccine; 1997 Jun; 15(8):884-7. PubMed ID: 9234539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
    zur Megede J; Chen MC; Doe B; Schaefer M; Greer CE; Selby M; Otten GR; Barnett SW
    J Virol; 2000 Mar; 74(6):2628-35. PubMed ID: 10684277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.